News Releases

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology
May 20, 2022
Read More
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
BUILDING A SOLID BASE OF VAZALORE ® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ( $0.39 ) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ( $0.66 ) Cash
May 13, 2022
Read More
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
SPARTA, N.J. , April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc.  (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many
April 22, 2022
Read More
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Momentum Building for Novel Vazalore ® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021 Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter
March 11, 2022
Read More
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022
SPARTA, N.J. , March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
March 1, 2022
Read More
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update
SPARTA, N.J. , Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc.  (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
February 22, 2022
Read More
PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness
-- Female-Led Company Strives to Transform Standard of Care  in Secondary Prevention of Heart Attack or Clot-Related Stroke  with its Innovative New Aspirin Formulation VAZALORE ®   -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a
February 3, 2022
Read More
PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications
SPARTA, N.J. , Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs
January 19, 2022
Read More